Olema Pharmaceuticals (OLMA) Projected to Post Earnings on Tuesday

Key Points

• Olema Pharmaceuticals (OLMA) is set to announce its Q2 2025 earnings on **August 5th**, with analysts expecting a loss of **$0.44** per share.
• In its last earnings report, Olema beat expectations by reporting a loss of **$0.36** EPS, which was better than the consensus estimate of **$0.49**.
• Multiple analysts have issued recent ratings and target price adjustments for Olema, with HC Wainwright maintaining a "buy" rating and setting a **$30.00** price objective.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) is anticipated to release its Q2 2025 earnings data before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.13. On average, analysts expect Olema Pharmaceuticals to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Olema Pharmaceuticals Stock Up 3.7%

Shares of NASDAQ:OLMA traded up $0.19 on Friday, hitting $5.33. The company had a trading volume of 707,091 shares, compared to its average volume of 904,636. The firm's 50-day simple moving average is $4.56 and its two-hundred day simple moving average is $4.68. Olema Pharmaceuticals has a 1 year low of $2.86 and a 1 year high of $14.41. The firm has a market capitalization of $364.68 million, a price-to-earnings ratio of -2.65 and a beta of 1.90.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a research report on Monday, April 28th. Oppenheimer decreased their target price on shares of Olema Pharmaceuticals from $25.00 to $22.00 and set an "outperform" rating for the company in a report on Wednesday, May 14th. Finally, The Goldman Sachs Group decreased their target price on shares of Olema Pharmaceuticals from $20.00 to $18.00 and set a "buy" rating for the company in a report on Wednesday, May 14th.

Hedge Funds Weigh In On Olema Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. increased its stake in Olema Pharmaceuticals by 93.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 741,329 shares of the company's stock worth $2,787,000 after buying an additional 358,412 shares during the period. Jane Street Group LLC increased its stake in Olema Pharmaceuticals by 216.8% in the 1st quarter. Jane Street Group LLC now owns 138,552 shares of the company's stock worth $521,000 after buying an additional 94,815 shares during the period. Finally, AQR Capital Management LLC purchased a new position in Olema Pharmaceuticals in the 1st quarter worth about $172,000. Institutional investors own 91.78% of the company's stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.